Wells Fargo
IBRX icon

Wells Fargo’s ImmunityBio IBRX Stock Holding History

Wells Fargo’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.9K Buy
+6,500
New +$44.5K ﹤0.01% 5455

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Wells Fargo's IBRX Position: Q1 2026 in Review

Wells Fargo reduced its ImmunityBio (IBRX) stake by 0.23% in Q1 2026, selling an estimated $8.21K and leaving 514,721 shares worth $3.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2790.

Wells Fargo first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Wells Fargo held 514,721 shares of ImmunityBio worth $3.95M as of Q1 2026.
  • Wells Fargo sold 1,199 ImmunityBio shares in Q1 2026, an estimated $8.21K.
  • ImmunityBio made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2790 holding.
  • Wells Fargo first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.